T. Sun

发表

Case report: Identification of a novel heterozygous germline ERCC2 mutation in a patient with dermatofibrosarcoma protuberans

Yi Ding, X. You, Qing Zhang, 2022, Frontiers in Oncology.

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma

Yu Gu, X. You, Jing Meng, 2022, Frontiers in Oncology.

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies

L. Shen, Zuhua Chen, Y. Shao, 2020, Clinical and translational medicine.

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

S. Shreeve, K. Patel, J. Curtin, 2021 .

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Yi-long Wu, L. Shen, D. Ye, 2020, Journal for immunotherapy of cancer.

Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide‐induced high tumor mutational burden

L. Shen, Y. Shao, Ming Lu, 2020, Cancer communications.

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Yang Luo, Bing-he Xu, Y. Shao, 2021, Cancer biology & medicine.

Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity

Taiyan Guo, X. You, Yaoqiang Wu, 2022, Frontiers in Oncology.

Glioma Imaging by O-(2-18F-Fluoroethyl)-L-Tyrosine PET and Diffusion-Weighted MRI and Correlation With Molecular Phenotypes, Validated by PET/MR-Guided Biopsies

Zhigang Qi, Xinru Xiao, Hongwei Yang, 2021, Frontiers in Oncology.

Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas

Weifeng Liu, Qing Zhang, Yongkun Yang, 2023, Frontiers in oncology.